Clinical trial

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

NCT07637942

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Every 4-week long-acting injectable cabotegravir and rilpivirine Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Design: OBSERVATIONAL · Status: NOT YET RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeOBSERVATIONAL

Start date2026-10-15

PhaseN/A

Conditions

HIV -1 Infectionunresolved

Interventions

Every 4-week long-acting injectable cabotegravir and rilpivirineDRUG

Sponsors & collaborators

International Maternal Pediatric Adolescent AIDS Clinical Trials Grouplead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)collaborator

National Institute of Mental Health (NIMH)collaborator

Mapped research locations

HoustonTexas, United States1 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 BaltimoreMaryland, United States1 AtlantaGeorgia, United States1 AuroraColorado, United States1 The BronxNew York, United States1 La JollaCalifornia, United States1 MemphisTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07637942 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.